Compare YHGJ & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YHGJ | MRKR |
|---|---|---|
| Founded | 1975 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 23.0M |
| IPO Year | 2006 | 2010 |
| Metric | YHGJ | MRKR |
|---|---|---|
| Price | $3.17 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.25 |
| AVG Volume (30 Days) | 2.6K | ★ 145.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,953,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.84 | N/A |
| 52 Week Low | $0.47 | $0.81 |
| 52 Week High | $10.29 | $4.07 |
| Indicator | YHGJ | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 52.01 | 47.67 |
| Support Level | $0.67 | $1.36 |
| Resistance Level | $3.98 | $1.88 |
| Average True Range (ATR) | 0.24 | 0.12 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 72.02 | 43.24 |
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.